INVENTISBIO CO LTD: DURING STUDY PERIOD, NOMELCITINIB DEMONSTRATED A FAVORABLE SAFETY PROFILE AND GOOD TOLERABILITY

Reuters · 11/02 11:00

Please log in to view news